Next-Generation Radiopharmaceuticals Redefining Targeted Oncology
Designed to be the Most Potent Payload in Targeted Oncology
Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026
Deep Leadership Across Radiopharmaceutical and Drug Development
The Perspective Story in Four Parts
Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve
Radiopharmaceutical Therapy Is the Next Generation of Targeted Oncology
$45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue
VMT-α-NET, VMT01, PSV359, and PSV594 Address a Combined $45B+ Solid Tumor Market
Pipeline in Depth: The Data Behind Each Program
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Neuroendocrine Tumors VMT-α-NET
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis
VMT-α-NET Best Response Deepens Over Time
VMT-α-NET Responses Deepen Over Time
Spider Plot of Tumor Change Over Time by Patient
VMT-⍺-NET: Durable Disease Control Across All Doses
Best-in-class Safety Profile1
Blood Creatinine During Follow-up for All Patients Treated (n=68)
VMT-α-NET ’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Melanoma VMT01
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)
VMT01 Clinical Data Support Further Development
PSV359 Advanced Solid Tumors
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
CCK2R81 a potential first-in-class in selected solid tumors
Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa
Platform and Manufacturing
Optimizing Structural Chemistry:
Choosing the Right Isotope
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
Direct-to-Hospital Delivery through Integrated Isotope Production
Reaching the Largest Addressable Market with Regional Manufacturing
Financial Strength and IP
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade - The Platform Is Built; Pipeline Advancing
Abbreviations
APPENDIX – Backup Slides
Investment thesis
Engineering the Alpha Advantage in Targeted Oncology
Optimizing the Entire System for Targeted Oncology
Advancing a Diverse 212Pb-Based Oncology Portfolio
Market opportunity
Solid Tumors are an Attractive Market for Radiopharmaceuticals
NETs Trials
Refractory Metastatic Melanoma Trials
VMT-α-NET
VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
VMT01
ICI Combo Rationale: Strong Synergy with VMT01 in Melanoma
Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01
Platform and Manufacturing
Construct Designed for Better Clinical Outcome
212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors
Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
IP protection
